Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition

Journal of Clinical Pharmacology

Volumn 49, Issue 2, 2009, Pages 212-218

  Kovarik, John M ^a   Dole, Kiran ^a   Riviere, Gilles Jacques ^a   Pommier, Francoise ^a   Maton, Steve ^a   Jin, Yi ^a   Lasseter, Kenneth C ^b   Schmouder, Robert L ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Clinical Pharmacology of Miami   (United States)

Author keywords

CYP4F2; Drug interactions; Fingolimod; Immunomodulators; Ketoconazole

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 4F2; FINGOLIMOD; IMMUNOMODULATING AGENT; KETOCONAZOLE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AEROBIC METABOLISM; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; LEUKOPENIA; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; OPEN STUDY; RASH; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL DISORDER; VOLUNTEER;

ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KETOCONAZOLE; MALE; MIDDLE AGED; PROPYLENE GLYCOLS; SPHINGOSINE; YOUNG ADULT;

EID: 58849124814     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008329553     Document Type: Article

References (12)

1. Brinkmann V., Lynch KR FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol. 2002 ; 14: 569-575.
2. Kappos L., Antel J., Comi G., et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006 ; 355: 1124-1140.
3. Kovarik JM, Schmouder RL, Slade AJ Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit. 2004 ; 26: 585-587.
4. Zollinger M., Gschwind HP, Jin Y., et al. Absorption and disposition of the immunomodulator compound FTY720 in healthy volunteers [Abstract]. Drug Metab Rev. 2008 ; 40 (S1). 125.
5. Stresser DM, Broudy MI, Thuy H., et al. Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos. 2004 ; 32: 105-112.
6. US Food and Drug Administration. Draft Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. 2006. http://www.fda.gov/cder/guidance/index.htm.
7. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabol Rev. 2002 ; 34: 83-448.
8. Wang MZ, Saulter JY, Usuki E., et al. CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289. Drug Metab Dispos. 2006 ; 34: 1985-1993.
9. Schultz M., Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie. 2003 ; 7: 447-474.
10. Schmouder RL, Barilla D., Wang Y., et al. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol. 2006 ; 46: 895-904.
11. Kovarik JM, Slade A., Riviere GJ, et al. The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. Br J Clin Pharmacol. 2008 ; 66: 199-206.
12. Kovarik JM, Schmouder RL, Barilla D., et al. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. Ann Pharmacother. 2004 ; 38: 1153-1158.